U.K. startup CellVoyant debuts AI platform that could radically reduce the cost of cell-based therapies such as CAR-T immunotherapy for cancer

British startup CellVoyant develops AI platform FateView that could dramatically reduce cell therapy production costs by up to 80%, potentially making advanced treatments like CAR-T immunotherapy more accessible and affordable for cancer patients.